CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution’s four clinical-stage RAS(ON) inhibitors to evaluate novel combination therapies for RAS-addicted cancers. Crucially, BeOne acquired exclusive rights […]

Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.

Revolution Medicines has delivered a very large 5 year return that leaves the stock looking expensive on Simply Wall St's valuation checks. The current move is now being judged as richly priced rather than a clear bargain. Revolution Medicines has returned about 7x over 5 years, which puts extra focus on whether recent enthusiasm has moved the share price ahead of fundamentals. Recent interest around the company's RAS(ON) inhibitors, including the BeOne Medicines collaboration and reported...

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne’s oncology assets with Revolution’s four clinical RAS(ON) inhibitors, alongside a regional licensing deal granting BeOne exclusive development and commercialization rights in select Asian markets and responsibility for funding a global Phase 3 trial. This arrangement gives Revolution Medicines access to BeOne’s development “superhighway,” milestone and royalty...

Revolution Medicines (RVMD) just entered a comprehensive partnership with BeOne Medicines that combines joint clinical development work and a regional rights deal in select Asian markets for its RAS(ON) oncology inhibitors. See our latest analysis for Revolution Medicines. The BeOne Medicines partnership lands at a time when Revolution Medicines has already seen strong momentum, with a 90 day share price return of 37.09% and year to date share price return of 160.12%, alongside a very large 1...

Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more than 400% over the past year, the question is whether this […]

The partnership will focus on developing combination therapies for patients with RAS-addicted cancers.

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Revolution Medicines Inc (RVMD) reports paradigm-changing Phase 3 results and a robust $3.9 billion cash position to fuel its commercial launch and expansive pipeline.

Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer. The company

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund […]

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer.

The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.

But is that performance sustainable?

Revolution Medicines recently reported that the FDA accepted its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, after the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma met all primary and key secondary endpoints with improved survival, quality of life and a manageable safety profile. The same data earned daraxonrasib priority pathways on both sides of the Atlantic, including the FDA Commissioner’s National...

Revolution Medicines stock has delivered very strong returns in recent years, yet its current valuation checks lean expensive. This sets up a clear tension between the share price momentum and what the broader metrics suggest about value. Revolution Medicines has returned about 6.4x over the past 3 years, which puts extra pressure on the current share price to be supported by the business outlook. The FDA review of daraxonrasib, supported by trial results in pancreatic cancer, can underpin...

Revolution Medicines (NasdaqGS:RVMD) reported that the FDA has accepted its New Drug Application for daraxonrasib following strong Phase 3 results. Daraxonrasib has been selected for the FDA Commissioner's National Priority Voucher program, with U.S. regulatory review now formally underway. Regulatory assessment for daraxonrasib has also started in Europe, with both U.S. and European authorities reviewing the treatment for pancreatic cancer. Revolution Medicines focuses on targeted oncology...

Revolution Medicines (RVMD) drew fresh attention after reporting that its experimental treatment daraxonrasib nearly doubled survival for pancreatic cancer patients who had exhausted other options, raising questions about how this data might influence the stock. See our latest analysis for Revolution Medicines. The survival data for daraxonrasib has arrived alongside strong recent trading in Revolution Medicines, with the share price returning 39.86% over 90 days and a year to date share...

If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race.

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company’s cash position as it prepares for a potential U.S. regulatory decision later this year.

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

Revolution Medicines could be a revolutionary biotech stock.